@inbook{d45949bbd5e74140b603692d95f7065e,
title = "CoVaccine HT{\texttrademark} adjuvant is superior to Freund's in eliciting ovine polyclonal antibodies against human tumor necrosis factor-alpha",
abstract = "Introduction: Passive immunotherapy using polyclonal antibodies plays an important role in preventing and treating antigenic and pathogenic diseases. Polyclonal antibodies are used for therapeutic, diagnostic and investigational purposes, with adjuvants employed to enhance the immune response against proteins that are poorly antigenic or self-antigens. This study aimed to optimize current immunization methods by evaluating the novel adjuvant CoVaccine HT{\texttrademark} against the established Freund's at producing ovine polyclonal antibodies against pro-inflammatory cytokine human recombinant tumor necrosis factor alpha (TNF-α). Methods: Castrated male Aberfield cross sheep were immunized with TNF-α in CoVaccine HT{\texttrademark} or Freund's adjuvant. The binding titer of antibodies for TNF-α and neutralization titer were determined in vitro, as well as the strength of antibody binding by a simple small scale affinity chromatography elution experiment. Animal welfare was monitored through inspection of immunization site reactions at regular time points and graded according to reaction size. The second part of the study looked at re-immunization using Freund's adjuvant alone every 4- or 8-weeks. Results: Freund's generated significantly higher antibody binding titers than CoVaccine HT{\texttrademark} but were less effective at neutralizing TNF-alpha which is a better indicator of functional potency. CoVaccine HT{\texttrademark} also caused fewer immunization site reactions, while no statistical difference was observed in the binding strength of antibodies. Re-immunization every 4- and 8-weeks showed no statistical difference. Conclusion: This study provides evidence that CoVaccine HT{\texttrademark} is superior to Freund's adjuvant for the production of antibodies to TNF-α, and supports the use of this alternative adjuvant for clinical and experimental use. The outcomes gained through this study are applicable to passive and active immunotherapy for the generation of polyclonal antibodies in human and veterinary medicine.",
keywords = "Adjuvant, Anti-TNF-α, CoVaccine HT{\texttrademark}, Freund's, Hyperimmunized serum, Immunization, Ovine, Polyclonal antibodies, Tumor necrosis factor-alpha",
author = "Griffiths, {Owen R.} and John Landon and Morris, {R. Keith} and James, {Philip E.} and Adams, {Rachel A.}",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = jan,
doi = "10.1016/bs.apcsb.2021.11.009",
language = "English",
isbn = "9780323992275",
series = "Advances in Protein Chemistry and Structural Biology",
publisher = "Elsevier",
pages = "189--213",
editor = "Rossen Donev",
booktitle = "Immunotherapeutics",
}